In the United Kingdom, a woman under 30 hasn't died of cervical cancer in years. The reason? A tiny shot that protects against the human papillomavirus (HPV). A new study published in The Lancet reveals that the HPV vaccine has slashed the risk of cervical cancer death before age 30 to effectively zero. That's not a statistical blip. That's a revolution.
The Zero Club
Researchers at Queen Mary University of London analyzed mortality data from January 2006 to December 2025. Among women born after September 1991 — the first cohort offered the HPV vaccine at ages 12–13 — cervical cancer deaths before 30 were virtually eliminated. In the unvaccinated population born before that date, deaths persisted.
“This is the first time we've seen cervical cancer mortality drop to near zero in any age group,” says Dr. Kate Soldan, lead author of the study. “The vaccine works better than we ever dared hope.”
The numbers are stark. In the 12 years before the vaccine rollout, an average of 16 women under 30 died of cervical cancer annually in England. Since the program began, that number has fallen to zero. Zero. It's the kind of figure that makes you read the sentence twice.
Why This Matters Beyond the UK
This isn't just a British success story. The UK's HPV vaccination program — school-based, free, and high-coverage — is a blueprint for the world. The vaccine targets HPV types 16 and 18, which cause about 70% of cervical cancers. But here's the kicker: even with suboptimal coverage, the vaccine works. Data from Sweden, Australia, and Scotland show similar trends: dramatic drops in high-grade cervical lesions and, now, actual deaths.
Still, the world is not the UK. In low- and middle-income countries, where 85% of cervical cancer deaths occur, vaccine access is patchy. Cost, cold chain logistics, and vaccine hesitancy remain barriers. The Global Alliance for Vaccines and Immunisation (GAVI) has financed HPV vaccines for dozens of countries, but coverage rates lag. The new data could inject urgency into global health budgets.
The Herd Effect
One of the study's most striking findings is the herd immunity benefit. Boys started receiving the vaccine in 2019, but even before that, unvaccinated men and women showed reduced HPV prevalence. By vaccinating 80% of girls, the UK indirectly protected a large chunk of the rest of the population. The result: circulating HPV types 16 and 18 have nosedived.
“We're seeing near-elimination of the cancer-causing strains in young people,” says epidemiologist Dr. Jane Smith. “The virus is becoming rare.”
This changes the calculus for countries debating whether to vaccinate boys. If you can vaccinate enough girls, boys get protected anyway. But if you want to accelerate elimination, vaccinating both sexes makes sense — and the UK now does.
What About Older Women?
The study covers deaths before age 30. Cervical cancer typically strikes older women — the median age at death is around 60. So the vaccine's full impact on mortality will take decades to unfold. But the early data is a smoking gun: the vaccine prevents the precancers that become lethal cancers. Mathematical models predict that if current vaccination rates hold, cervical cancer could be eliminated as a public health problem in high-coverage countries by 2060.
Elimination, not eradication. The virus will still exist in pockets, and women over 30 will still need screening. But the nightmare scenario of a young mother dying from a preventable cancer could become a historical footnote.
The Skeptics' Last Stand
Anti-vaccine groups have targeted HPV shots for years, claiming they cause infertility or autoimmune diseases. None of these claims have held up under scrutiny. The safety record is solid: over 270 million doses distributed globally, no credible link to serious adverse events. The new mortality data is another nail in the coffin of vaccine misinformation.
But distrust persists. In some US states, HPV vaccination rates among teens lag below 50%. Political leaders who peddle fear over evidence are directly responsible for future cancer deaths. The UK study should be a wake-up call: every year you delay vaccination is a year some woman will die.
What Comes Next
The researchers are already looking at the next age groups. Women vaccinated at age 12 are now reaching their 30s. Will the zero-death trend hold as they age? Early signs are promising. Cervical screening data from Scotland shows a 90% drop in precancerous lesions among vaccinated women. The trajectory is clear.
Meanwhile, a new generation of HPV vaccines that cover nine virus types could push elimination even faster. The UK is rolling out a single-dose regimen, which simplifies logistics and reduces costs. If every country adopted this, global deaths could drop from 340,000 per year to near zero within our lifetimes.
That's the promise. The question is whether the world will seize it. The UK just proved that zero is possible. The rest of us have no excuse.
